Cor Plans Integrelin Filing In 1Q96
Cor Therapeutics has decided to go ahead and file a New Drug Application for Integrelin, its glycoprotein IIb/IIIa receptor antagonist, and forecasts that this will be sometime in the first quarter of 1996. The application will be based on the results of the IMPACT II study, which were presented at the European Society of Cardiology meeting in 1995.
IMPACT II provided mixed results - the drug demonstrated a significant effect on the primary composite endpoint of all-cause mortality, myocardial infarction or the need for revascularization/stent placement at 24 hours, but appeared to have no preventive effects on the rate of restenosis, as was seen in the EPIC trial of Centocor's ReoPro (abciximab; Marketletter September 11, 1995). Schering-Plough is Cor's worldwide development partner for Integrelin.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze